REFERENCES
- Gilbert, F., A.R. Harris, and R.M. I. Kapsa. 2014. Controlling brain cells with light: Ethical considerations for optogenetic clinical trials. AJOB Neuroscience 5(3): 3–11.
- Hess, P. 2012. Intracranial stem cell-based transplantation: Reconsidering the ethics of phase 1 clinical trials in light of irreversible interventions in the brain. AJOB Neuroscience 3(2): 3–13.
- Katsuno, M., H. Watanabe, F. Tanaka, and G. Sobue. 2010. Translational research on disease‐modifying therapies for neurodegenerative diseases. Neurology and Clinical Neuroscience 1(1): 3–10.
- Kimmelman, J. 2009. Gene transfer and the ethics of first-in-human research: Lost in translation. New York, NY: Cambridge University Press.
- Lang, A.E. 2010. Clinical trials of disease-modifying therapies for neurodegenerative diseases: The challenges and the future. Nature Medicine 16(11): 1223–1226.
- Martin, R.A., and J.S. Robert. 2007. Is risky pediatric research without prospect of direct benefit ever justified? American Journal of Bioethics 7(3): 12–15.
- Selden, N.R., A. Al-Uzri, S.L. Huhn, et al. 2013. Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis: Clinical article. Journal of Neurosurgery: Pediatrics 11(6): 643–652.
- Yarborough, M., T. Tempkin, J. Nolta, and N. Joyce. 2012. The complex ethics of first in human stem cell clinical trials. AJOB Neuroscience 3(2): 14–16.
- World Medical Association. 2008. WMA Declaration of Helsinki—Ethical principles for medical research involving human subjects 2008. 59th WMA General Assembly, Seoul, October.